Communiqués ViroGates A/S

Actions

VIRO

DK0061030574

Recherche biotechnologique et médicale

Temps Différé Nasdaq Copenhagen 17:20:00 09/09/2026			Varia. 5j.	Varia. 1 janv.
10,90 ^DKK	-1,80%		-1,80%	-18,96%

21/08	Transcript : ViroGates A/S, H1 2026 Earnings Call, Aug 21, 2026
20/08	ViroGates A/S publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

20/08	ViroGates announces its half-year report for H1 2026	AQ
18/08	ViroGates publishes its half-year report for the first half of 2026 on 20 August and invites to a webinar on 21 August 2026	AQ
13/08	ViroGates announces revised financial guidance for 2026	AQ
03/08	ViroGates announces changes to its commercial organization	AQ
07/05	ViroGates announces its Interim Report for Q1-2026	AQ
23/04	Resolutions from the Annual General Meeting of ViroGates A/S	AQ
08/04	ViroGates submits its De Novo application to the U.S. FDA for suPARnostic® TurbiLatex	AQ
08/04	ViroGates gives notice to convene the Annual General Meeting on 23 April 2026	AQ
26/03	ViroGates A/S : Vederlagsrapport 2025 IQBuog55q2KEQLeLnMyaJXFEAZgnwj7tsLwtfQ6WLGZvPls?e=hcEACs	PU
26/03	ViroGates A/S : Årsrapport 2025	PU
26/03	ViroGates announces its Annual Report 2025: Revenue growth and improved operating result as strategic transition towards preventive health and longevity continues	AQ
12/12	ViroGates publishes its financial calendar for 2026	AQ
12/12	ViroGates announces financial guidance for 2026	AQ
28/11	ViroGates’ capital raise of DKK 19.3 million and issue of 1,547,412 shares have been registered and settled	AQ
20/11	SuPAR Remedy, LLC announces the Completion of the public tender offer to the shareholders of ViroGates.	AQ
18/11	ViroGates announces a directed issue of nominally 1,547,412 shares, raising approximately DKK 19.3 million	AQ
17/11	ViroGates announces a plan to offer new shares through a directed issue without preemptive rights for existing shareholders	AQ
12/11	SuPAR Remedy, LLC announces the outcome of the Public Tender Offer to the shareholders of ViroGates.	AQ
06/11	ViroGates A/S : 20251106 ViroGates Interim Report, Q1 Q3 2025 VF	PU
06/11	ViroGates announces its Interim Report for Q1-Q3 2025	AQ
23/10/25	ViroGates announces Notice of Potential Equity / Capital Raise	AQ
17/10/25	ViroGates Receives FDA Feedback on 513(g) Request, confirming Regulatory Pathway for U.S. Market Entry	AQ
15/10/25	ViroGates announces the publication of a Board Statement in relation to the Tender Offer from suPAR Remedy, LLC	AQ
10/10/25	ViroGates announces the receipt of an Announcement and Official Tender Offer Document from suPAR Remedy LLC	AQ
08/10/25	SuPAR Remedy, LLC announces public tender offer to the shareholders of ViroGates A/S at a 40% premium	AQ